Boehringer discontinues brigimadlin while others continue to struggle.

One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.

A just revealed clinical trial listing shows Ascentage’s BCL-2 inhibitor being compared against an outdated standard of care.